OmniAb Inc (OABI)
OmniAb Inc. is a biotechnology company listed on NASDAQ under the ticker OABI. The company licenses discovery research technology to pharmaceutical and biotechnology companies as well as academic institutions to support therapeutic discovery in the United States, Europe, Japan, China, and Canada. Its platform is designed to generate and screen diverse antibody repertoires to help identify target-binding proteins for drug development programs. OmniAb also develops a range of proprietary and engineered animal-based technologies, including OmniRat, OmniChicken, and OmniMouse, along with bispecific discovery platforms such as OmniFlic and OmniClic, the cow-inspired OmniTaur system, the single-domain antibody platform OmnidAb, and the OmniDeep suite of in silico AI and machine learning tools. The company was founded in 2012 and is headquartered in Emeryville, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OABI
|
$2.24
|
7.4% Upside
|
Fair
|
$7.33
|
251.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-5.5x
|
1.1x
|
10.4x
|
301.5 M
|
271.4 M
|
6.1%
|
78.5%
|
2.2
|
—
|
47.9%
|
